An FtsZ-targeting prodrug with oral antistaphylococcal efficacy in vivo

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 5860-5869

  Kaul, Malvika ^a   Mark, Lilly ^b   Zhang, Yongzheng ^b   Parhi, Ajit K ^b   LaVoie, Edmond J ^c   Pilch, Daniel S ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b TAXIS Pharmaceuticals Inc   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BENZAMIDE DERIVATIVE; ERYTHROMYCIN; FTSZ PROTEIN; OXACILLIN; PC 190723; PRODRUG; TXY 436; UNCLASSIFIED DRUG; VANCOMYCIN; BACTERIAL PROTEIN; CYTOSKELETON PROTEIN; FTSZ PROTEIN, BACTERIA; PC190723; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE; TXY436;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG SYNTHESIS; FEMALE; HYDROPHOBICITY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PERITONITIS; PH; PHASE CONTRAST MICROSCOPY; PRIORITY JOURNAL; PROTEIN POLYMERIZATION; STEADY STATE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOAVAILABILITY; BIOTRANSFORMATION; CHLOROCEBUS AETHIOPS; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HALF LIFE TIME; METABOLISM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; STAPHYLOCOCCAL INFECTIONS; VERO CELL LINE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BENZAMIDES; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CERCOPITHECUS AETHIOPS; CYTOSKELETAL PROTEINS; FEMALE; HALF-LIFE; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; PRODRUGS; PYRIDINES; STAPHYLOCOCCAL INFECTIONS; THIAZOLES; VERO CELLS;

EID: 84887453149     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01016-13     Document Type: Article

References (43)

1. Bi EF, Lutkenhaus J. 1991. FtsZ ring structure associated with division in Escherichia coli. Nature 354:161-164.
2. Errington J, Daniel RA, Scheffers DJ. 2003. Cytokinesis in bacteria. Microbiol. Mol. Biol. Rev. 67:52-65.
3. Adams DW, Errington J. 2009. Bacterial cell division: assembly, maintenance, and disassembly of the Z ring. Nat. Rev. Microbiol. 7:642-653.
4. Kirkpatrick CL, Viollier PH. 2011. New(s) to the (Z-)ring. Curr. Opin. Microbiol. 14:691-697.
5. Erickson HP, Anderson DE, Osawa M. 2010. FtsZ in bacterial cytokinesis: cytoskeleton and force generator all in one. Microbiol. Mol. Biol. Rev. 74:504-528.
6. Stokes NR, Sievers J, Barker S, Bennett JM, Brown DR, Collins I, Errington VM, Foulger D, Hall M, Halsey R, Johnson H, Rose V, Thomaides HB, Haydon DJ, Czaplewski LG, Errington J. 2005. Novel inhibitors of bacterial cytokinesis identified by a cell-based antibiotic screening assay. J. Biol. Chem. 280:39709-39715.
7. Haydon DJ, Stokes NR, Ure R, Galbraith G, Bennett JM, Brown DR, Baker PJ, Barynin VV, Rice DW, Sedelnikova SE, Heal JR, Sheridan JM, Aiwale ST, Chauhan PK, Srivastava A, Taneja A, Collins I, Errington J, Czaplewski LG. 2008. An inhibitor of FtsZ with potent and selective antistaphylococcal activity. Science 321:1673-1675.
8. Huang Q, Kirikae F, Kirikae T, Pepe A, Amin A, Respicio L, Slayden RA, Tonge PJ, Ojima I. 2006. Targeting FtsZ for antituberculosis drug discovery: noncytotoxic taxanes as novel antituberculosis agents. J. Med. Chem. 49:463-466.
9. Czaplewski LG, Collins I, Boyd EA, Brown D, East SP, Gardiner M, Fletcher R, Haydon DJ, Henstock V, Ingram P, Jones C, Noula C, Kennison L, Rockley C, Rose V, Thomaides-Brears HB, Ure R, Whittaker M, Stokes NR. 2009. Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ. Bioorg. Med. Chem. Lett. 19:524-527.
10. Schaffner-Barbero C, Martin-Fontecha M, Chacón P, Andreu JM. 2012. Targeting the assembly of bacterial cell division protein FtsZ with small molecules. ACS Chem. Biol. 7:269-277.
11. Ma S. 2012. The development of FtsZ inhibitors as potential antibacterial agents. ChemMedChem 7:1161-1172.
12. Haydon DJ, Bennett JM, Brown D, Collins I, Galbraith G, Lancett P, Macdonald R, Stokes NR, Chauhan PK, Sutariya JK, Nayal N, Srivastava A, Beanland J, Hall R, Henstock V, Noula C, Rockley C, Czaplewski L. 2010. Creating an antibacterial with in vivo efficacy: synthesis and characterization of potent inhibitors of the bacterial cell division protein FtsZ with improved pharmaceutical properties. J. Med. Chem. 53:3927-3936.
13. Andreu JM, Schaffner-Barbero C, Huecas S, Alonso D, Lopez-Rodriguez ML, Ruiz-Avila LB, Núñez-Ramírez R, Llorca O, Martín-Galiano AJ. 2010. The antibacterial cell division inhibitor PC190723 is an FtsZ polymer-stabilizing agent that induces filament assembly and condensation. J. Biol. Chem. 285:14239-14246.
14. Lock RL, Harry EJ. 2008. Cell-division inhibitors: new insights for future antibiotics. Nat. Rev. Drug Discov. 7:324-338.
15. Boberek JM, Stach J, Good L. 2010. Genetic evidence for inhibition of bacterial division protein FtsZ by berberine. PLoS One 5:e13745. doi:10.1371/journal.pone.0013745.
16. Awasthi D, Kumar K, Ojima I. 2011. Therapeutic potential of FtsZ inhibition: a patent perspective. Expert Opin. Ther. Patents 21:657-679.
17. Huang Q, Tonge PJ, Slayden RA, Kirikae T, Ojima I. 2007. FtsZ: a novel target for tuberculosis drug discovery. Curr. Top. Med. Chem. 7:527-543.
18. Kumar K, Awasthi D, Berger WT, Tonge PJ, Slayden RA, Ojima I. 2010. Discovery of anti-TB agents that target the cell-division protein FtsZ. Future Med. Chem. 2:1305-1323.
19. Kumar K, Awasthi D, Lee SY, Zanardi I, Ruzsicska B, Knudson S, Tonge PJ, Slayden RA, Ojima I. 2011. Novel trisubstituted benzimidazoles, targeting Mtb FtsZ, as a new class of antitubercular agents. J. Med. Chem. 54:374-381.
20. Kapoor S, Panda D. 2009. Targeting FtsZ for antibacterial therapy: a promising avenue. Expert Opin. Ther. Targets 13:1037-1051.
21. Kaul M, Parhi AK, Zhang Y, LaVoie EJ, Tuske S, Arnold E, Kerrigan JE, Pilch DS. 2012. A bactericidal guanidinomethyl biaryl that alters the dynamics of bacterial FtsZ polymerization. J. Med. Chem. 55:10160-10176.
22. Kelley C, Zhang Y, Parhi A, Kaul M, Pilch DS, LaVoie EJ. 2012. 3-Phenyl substituted 6, 7-dimethoxyisoquinoline derivatives as FtsZtargeting antibacterial agents. Bioorg. Med. Chem. 20:7012-7029.
23. Kelley C, Lu S, Parhi A, Kaul M, Pilch DS, LaVoie EJ. 2013. Antimicrobial activity of various 4- and 5-substituted 1-phenylnaphthalenes. Eur. J. Med. Chem. 60:395-409.
24. Parhi A, Lu S, Kelley C, Kaul M, Pilch DS, LaVoie EJ. 2012. Antibacterial activity of substituted dibenzo[a, g]quinolizin-7-ium derivatives. Bioorg. Med. Chem. Lett. 22:6962-6966.
25. Zhang Y, Giurleo D, Parhi A, Kaul M, Pilch DS, LaVoie EJ. 2013. Substituted 1, 6-diphenylnaphthalenes as FtsZ-targeting antibacterial agents. Bioorg. Med. Chem. Lett. 23:2001-2006.
26. Stokes NR, Baker N, Bennett JM, Berry J, Collins I, Czaplewski LG, Logan A, Macdonald R, Macleod L, Peasley H, Mitchell JP, Nayal N, Yadav A, Srivastava A, Haydon DJ. 2013. An improved small-molecule inhibitor of FtsZ with superior in vitro potency, drug-like properties, and in vivo efficacy. Antimicrob. Agents Chemother. 57:317-325.
27. Adams DW, Wu LJ, Czaplewski LG, Errington J. 2011. Multiple effects of benzamide antibiotics on FtsZ function. Mol. Microbiol. 80:68-84.
28. Sorto NA, Olmstead MM, Shaw JT. 2010. Practical synthesis of PC190723, an inhibitor of the bacterial cell division protein FtsZ. J. Org. Chem. 75:7946-7949.
29. CLSI. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 8th ed. Document M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
30. Gueiros-Filho FJ, Losick R. 2002. A widely conserved bacterial cell division protein that promotes assembly of the tubulin-like protein FtsZ. Genes Dev. 16:2544-2556.
31. O'Neill AJ, Cove JH, Chopra I. 2001. Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus. J. Antimicrob. Chemother. 47:647-650.
32. Stiles BG, Campbell YG, Castle RM, Grove SA. 1999. Correlation of temperature and toxicity in murine studies of staphylococcal enterotoxins and toxic shock syndrome toxin 1. Infect. Immun. 67:1521-1525.
33. Ekins S, Reynolds RC, Kim H, Koo M-S, Ekonomidis M, Talaue M, Paget SD, Woolhiser LK, Lenaerts AJ, Bunin BA, Connell N, Freundlich JS. 2013. Bayesian models leveraging bioactivity and cytotoxicity information for drug discovery. Chem. Biol. 20:370-378.
34. Bundgaard H, Johansen M. 1980. Prodrugs as drug delivery systems. IV. N-Mannich bases as potential novel prodrugs for amides, ureides, amines, and other NH-acidic compounds. J. Pharm. Sci. 69:44-46.
35. Huttunen KM, Rautio J. 2011. Prodrugs: an efficient way to breach delivery and targeting barriers. Curr. Top. Med. Chem. 11:2265-2287.
36. Dhareshwar SS, Stella VJ. 2008. Your prodrug releases formaldehyde: should you be concerned? No! J. Pharm. Sci. 97:4184-4193.
37. Tan CM, Therien AG, Lu J, Lee SH, Caron A, Gill CJ, Lebeau-Jacob C, Benton-Perdomo L, Monteiro JM, Pereira PM, Elsen NL, Wu J, Deschamps K, Petcu M, Wong S, Daigneault E, Kramer S, Liang L, Maxwell E, Claveau D, Vaillancourt J, Skorey K, Tam J, Wang H, Meredith TC, Sillaots S, Wang-Jarantow L, Ramtohul Y, Langlois E, Landry F, Reid JC, Parthasarathy G, Sharma S, Baryshnikova A, Lumb KJ, Pinho MG, Soisson SM, Roemer T. 2012. Restoring methicillin-resistant Staphylococcus aureus susceptibility to β-lactam antibiotics. Sci. Transl. Med. 4:126ra135.
38. Jorge AM, Hoiczyk E, Gomes JP, Pinho MG. 2011. EzrA contributes to the regulation of cell size in Staphylococcus aureus. PLoS One 6:e27542. doi:10.1371/journal.pone.0027542.
39. Kaul M, Zhang Y, Parhi AK, LaVoie EJ, Tuske S, Arnold E, Kerrigan JE, Pilch DS. 2013. Enterococcal and streptococcal resistance to PC190723 and related compounds: molecular insights from a FtsZ mutational analysis. Biochimie 95:1880-1887.
40. Haeusser DP, Garza AC, Buscher AZ, Levin PA. 2007. The division inhibitor EzrA contains a seven-residue patch required for maintaining the dynamic nature of the medial FtsZ ring. J. Bacteriol. 189:9001-9010.
41. Haeusser DP, Schwartz RL, Smith AM, Oates ME, Levin PA. 2004. EzrA prevents aberrant cell division by modulating assembly of the cytoskeletal protein FtsZ. Mol. Microbiol. 52:801-814.
42. Ma X, Ehrhardt DW, Margolin W. 1996. Colocalization of cell division proteins FtsZ and FtsA to cytoskeletal structures in living Escherichia coli cells by using green fluorescent protein. Proc. Natl. Acad. Sci. U. S. A. 93:12998-13003.
43. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, Fukuchi Y, Kobayashi I. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673.